Intellipharmaceutics International Inc. (Nasdaq:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) stock opened at $4.03 in last trading session, and closed at $3.63, trading in the range of $3.58 – $4.08. The stock showed a negative weekly performance of -10.59%.
Ladenburg Thalmann upgraded shares of Genetic Technologies (NASDAQ:GENE) from a neutral rating to a buy rating in a research report released on Thursday, TheFlyOnTheWall.com reports. The firm currently has $2.50 price target on the stock. Genetic Technologies Limited (ADR)(NASDAQ:GENE) shares closed at $1.74 on last trade day, by losing -8.42%. Stock 52 week range is $1.30 – $3.35. Company’s market capitalization is $27.58 million.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company. The Company is focused on the development of treatments that inhibits the activity of galectins as a means of treating human diseases, such as cancer and chronic organ failure. The Company was focused on the development and testing of Riquent as a treatment for Lupus nephritis. On January 19, 2012, the Company acquired rights to certain assets, including a clinical-stage compound designated GCS-100, from Solana Therapeutics, Inc. (Solana). La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock decreased -5.09% and finished the last session at $7.84. The EPS of the stock remained -37.39. Company’s market capitalization is $34.53 billion.
Alcobra Ltd (NASDAQ:ADHD) average recommendation is buy with average Target Price of $35.00. Alcobra Ltd (NASDAQ:ADHD) stock opened at $22.02 in last trading session and closed at $20.55. The 52 week range of the stock is $6.50 – $26.96 and the day range was $20.55 – $22.02.